Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma is a research paper published in New England Journal of Medicine (2024). On theSindex it has a DataRank of 3.4. It has been cited 211 times, with 100 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.803
From this paper's citation signal
Citation Network Contribution
2.6
From 73 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
National Cancer Institute, National Institutes of Health
Grant: U10CA180819
National Cancer Institute, National Institutes of Health
Grant: U10CA180820
National Cancer Institute, National Institutes of Health
Grant: U10CA180821
National Cancer Institute, National Institutes of Health
Grant: U10CA180863
National Cancer Institute, National Institutes of Health
Grant: U10CA180888
National Cancer Institute, National Institutes of Health
Grant: UG1CA189955
NCI NIH HHS
Grant: P30 CA093373
NCI NIH HHS
Grant: R50 CA285409
NCI NIH HHS
Grant: R50 CA285492
NCI NIH HHS
Grant: UG1 CA233230
NCI NIH HHS
Grant: UG1 CA233160
NCI NIH HHS
Grant: P30 CA008748
SeaGen
Bristol-Myers Squibb
FWCI
64.88
Citation Percentile
1.0%
Influential Citations
4
Citation Trend
Fields of Study
MeSH Terms
Keywords